Entera Bio Targets Q1 2026 FDA Submission for EB613 Osteoporosis Drug

Event summary

  • Entera Bio plans to submit final Phase 3 protocol for EB613 to FDA in Q1 2026, following December 2025 FDA ruling on BMD as regulatory endpoint.
  • Next-Gen EB613 Phase 1 bridging study results expected by end of Q1 2026.
  • Company to accelerate oral hypoparathyroidism tablet program in 2026 based on preclinical data.
  • Strategic partnership discussions advancing across pipeline.

The big picture

Entera Bio is advancing its oral peptide platform with strategic focus on underserved conditions in women's health. The company's progress in osteoporosis and hypoparathyroidism programs comes as biotech firms increasingly target oral delivery solutions for peptide therapies. Success in these areas could position Entera as a key player in transforming treatment paradigms for metabolic bone diseases.

What we're watching

Regulatory Alignment
Whether FDA's acceptance of BMD as regulatory endpoint will streamline EB613 approval process.
Clinical Progress
The pace at which Next-Gen EB613 bridging study results could impact development strategy.
Partnership Strategy
How potential partnerships might accelerate commercialization of Entera's oral peptide pipeline.